Human immunodeficiency virus type 1 pharmacogenomics in clinical practice: Relevance of HIV-1 drug resistance testing (part 1)

Roberto Patarca, Alejandro Isava, Rafael E Campo, Nelson J. Rodriguez, Enriqueta Nunez, Michael Alter, Margaret Marchette, Mirtha M. Sanabia, Charles D Mitchell, Delia Rivera-Hernandez, Gwendolyn B Scott, Dushyantha T Jayaweera, Jose Moreno, Catherine V Boulanger, Michael A Kolber, Cindy W. Mask, Eduardo Meneses Sierra, Ricardo Vallejo, John Page, Nancy G. KlimasMary Ann Fletcher

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Throughout most of the past century, physicians could offer patients no treatments for infections caused by viruses. The experience with treatment of infection by human immunodeficiency virus (HIV) has changed the way health-care workers deal with viral infections and has triggered a growing rate of discovery and use of antiviral agents, the first fruits of the expanding genomics revolution. HIV treatment also provides an informative paradigm for pharmacogenomics because control of infection and its consequences is limited by the development of viral drug resistance and by host factors. This report summarizes studies published to date on the significance of testing of HIV-1 resistance to antiretroviral drugs. The only Food and Drug Administration-approved kit for HIV drug resistance testing by genotypic sequencing is commercially available through Visible Genetics, Inc. Genotyping sequencing alone is most likely an adequate test to assist in the therapeutic decision-making process for previous regimen failure, for treatment-naïve patients in areas of high prevalence of transmitted resistant virus, and for pregnant women. However, in exceptional cases of highly complex mutation patterns and extensive cross-resistance, it may be useful to obtain a phenotype test, because that result may more easily identify drugs to which virus is least resistant. There are no published clinical trials results on the usefulness of the so-called virtual phenotype over genotypic sequencing alone. Not only has the paradigm of viral pharmacogenomics in the form of HIV genotypic sequencing been useful in treating other viral diseases, but it is also important to the real-life implementation of the growing discipline of genomics or molecular medicine. The application of this paradigm to the thousands of potential therapeutic targets that have become available through the various human genome projects will certainly gradually change the landscape of diagnosis and management of many diseases, including cancer.

Original languageEnglish
Pages (from-to)201-234
Number of pages34
JournalJournal of Environmental Pathology, Toxicology and Oncology
Volume22
Issue number3
DOIs
StatePublished - Sep 15 2003

Fingerprint

drug resistance
Pharmacogenetics
human immunodeficiency virus
Viruses
Drug Resistance
HIV-1
Virus Diseases
HIV
Testing
virus
Pharmaceutical Preparations
Genomics
Patient treatment
phenotype
genomics
drug
Viral Drug Resistance
Molecular Medicine
Human Genome Project
viral disease

Keywords

  • Antiretroviral treatment
  • Drug resistance testing
  • HIV-1
  • Mutations
  • Protease
  • Reverse transcriptase
  • Viral fitness
  • Virus infection

ASJC Scopus subject areas

  • Environmental Science(all)
  • Environmental Chemistry
  • Pathology and Forensic Medicine
  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Human immunodeficiency virus type 1 pharmacogenomics in clinical practice : Relevance of HIV-1 drug resistance testing (part 1). / Patarca, Roberto; Isava, Alejandro; Campo, Rafael E; Rodriguez, Nelson J.; Nunez, Enriqueta; Alter, Michael; Marchette, Margaret; Sanabia, Mirtha M.; Mitchell, Charles D; Rivera-Hernandez, Delia; Scott, Gwendolyn B; Jayaweera, Dushyantha T; Moreno, Jose; Boulanger, Catherine V; Kolber, Michael A; Mask, Cindy W.; Sierra, Eduardo Meneses; Vallejo, Ricardo; Page, John; Klimas, Nancy G.; Fletcher, Mary Ann.

In: Journal of Environmental Pathology, Toxicology and Oncology, Vol. 22, No. 3, 15.09.2003, p. 201-234.

Research output: Contribution to journalArticle

Patarca, Roberto ; Isava, Alejandro ; Campo, Rafael E ; Rodriguez, Nelson J. ; Nunez, Enriqueta ; Alter, Michael ; Marchette, Margaret ; Sanabia, Mirtha M. ; Mitchell, Charles D ; Rivera-Hernandez, Delia ; Scott, Gwendolyn B ; Jayaweera, Dushyantha T ; Moreno, Jose ; Boulanger, Catherine V ; Kolber, Michael A ; Mask, Cindy W. ; Sierra, Eduardo Meneses ; Vallejo, Ricardo ; Page, John ; Klimas, Nancy G. ; Fletcher, Mary Ann. / Human immunodeficiency virus type 1 pharmacogenomics in clinical practice : Relevance of HIV-1 drug resistance testing (part 1). In: Journal of Environmental Pathology, Toxicology and Oncology. 2003 ; Vol. 22, No. 3. pp. 201-234.
@article{a5d3749d5e124ef99ef77b67b3faf4b0,
title = "Human immunodeficiency virus type 1 pharmacogenomics in clinical practice: Relevance of HIV-1 drug resistance testing (part 1)",
abstract = "Throughout most of the past century, physicians could offer patients no treatments for infections caused by viruses. The experience with treatment of infection by human immunodeficiency virus (HIV) has changed the way health-care workers deal with viral infections and has triggered a growing rate of discovery and use of antiviral agents, the first fruits of the expanding genomics revolution. HIV treatment also provides an informative paradigm for pharmacogenomics because control of infection and its consequences is limited by the development of viral drug resistance and by host factors. This report summarizes studies published to date on the significance of testing of HIV-1 resistance to antiretroviral drugs. The only Food and Drug Administration-approved kit for HIV drug resistance testing by genotypic sequencing is commercially available through Visible Genetics, Inc. Genotyping sequencing alone is most likely an adequate test to assist in the therapeutic decision-making process for previous regimen failure, for treatment-na{\"i}ve patients in areas of high prevalence of transmitted resistant virus, and for pregnant women. However, in exceptional cases of highly complex mutation patterns and extensive cross-resistance, it may be useful to obtain a phenotype test, because that result may more easily identify drugs to which virus is least resistant. There are no published clinical trials results on the usefulness of the so-called virtual phenotype over genotypic sequencing alone. Not only has the paradigm of viral pharmacogenomics in the form of HIV genotypic sequencing been useful in treating other viral diseases, but it is also important to the real-life implementation of the growing discipline of genomics or molecular medicine. The application of this paradigm to the thousands of potential therapeutic targets that have become available through the various human genome projects will certainly gradually change the landscape of diagnosis and management of many diseases, including cancer.",
keywords = "Antiretroviral treatment, Drug resistance testing, HIV-1, Mutations, Protease, Reverse transcriptase, Viral fitness, Virus infection",
author = "Roberto Patarca and Alejandro Isava and Campo, {Rafael E} and Rodriguez, {Nelson J.} and Enriqueta Nunez and Michael Alter and Margaret Marchette and Sanabia, {Mirtha M.} and Mitchell, {Charles D} and Delia Rivera-Hernandez and Scott, {Gwendolyn B} and Jayaweera, {Dushyantha T} and Jose Moreno and Boulanger, {Catherine V} and Kolber, {Michael A} and Mask, {Cindy W.} and Sierra, {Eduardo Meneses} and Ricardo Vallejo and John Page and Klimas, {Nancy G.} and Fletcher, {Mary Ann}",
year = "2003",
month = "9",
day = "15",
doi = "10.1615/JEnvPathToxOncol.v22.i3.40",
language = "English",
volume = "22",
pages = "201--234",
journal = "Journal of Environmental Pathology, Toxicology and Oncology",
issn = "0731-8898",
publisher = "Begell House Inc.",
number = "3",

}

TY - JOUR

T1 - Human immunodeficiency virus type 1 pharmacogenomics in clinical practice

T2 - Relevance of HIV-1 drug resistance testing (part 1)

AU - Patarca, Roberto

AU - Isava, Alejandro

AU - Campo, Rafael E

AU - Rodriguez, Nelson J.

AU - Nunez, Enriqueta

AU - Alter, Michael

AU - Marchette, Margaret

AU - Sanabia, Mirtha M.

AU - Mitchell, Charles D

AU - Rivera-Hernandez, Delia

AU - Scott, Gwendolyn B

AU - Jayaweera, Dushyantha T

AU - Moreno, Jose

AU - Boulanger, Catherine V

AU - Kolber, Michael A

AU - Mask, Cindy W.

AU - Sierra, Eduardo Meneses

AU - Vallejo, Ricardo

AU - Page, John

AU - Klimas, Nancy G.

AU - Fletcher, Mary Ann

PY - 2003/9/15

Y1 - 2003/9/15

N2 - Throughout most of the past century, physicians could offer patients no treatments for infections caused by viruses. The experience with treatment of infection by human immunodeficiency virus (HIV) has changed the way health-care workers deal with viral infections and has triggered a growing rate of discovery and use of antiviral agents, the first fruits of the expanding genomics revolution. HIV treatment also provides an informative paradigm for pharmacogenomics because control of infection and its consequences is limited by the development of viral drug resistance and by host factors. This report summarizes studies published to date on the significance of testing of HIV-1 resistance to antiretroviral drugs. The only Food and Drug Administration-approved kit for HIV drug resistance testing by genotypic sequencing is commercially available through Visible Genetics, Inc. Genotyping sequencing alone is most likely an adequate test to assist in the therapeutic decision-making process for previous regimen failure, for treatment-naïve patients in areas of high prevalence of transmitted resistant virus, and for pregnant women. However, in exceptional cases of highly complex mutation patterns and extensive cross-resistance, it may be useful to obtain a phenotype test, because that result may more easily identify drugs to which virus is least resistant. There are no published clinical trials results on the usefulness of the so-called virtual phenotype over genotypic sequencing alone. Not only has the paradigm of viral pharmacogenomics in the form of HIV genotypic sequencing been useful in treating other viral diseases, but it is also important to the real-life implementation of the growing discipline of genomics or molecular medicine. The application of this paradigm to the thousands of potential therapeutic targets that have become available through the various human genome projects will certainly gradually change the landscape of diagnosis and management of many diseases, including cancer.

AB - Throughout most of the past century, physicians could offer patients no treatments for infections caused by viruses. The experience with treatment of infection by human immunodeficiency virus (HIV) has changed the way health-care workers deal with viral infections and has triggered a growing rate of discovery and use of antiviral agents, the first fruits of the expanding genomics revolution. HIV treatment also provides an informative paradigm for pharmacogenomics because control of infection and its consequences is limited by the development of viral drug resistance and by host factors. This report summarizes studies published to date on the significance of testing of HIV-1 resistance to antiretroviral drugs. The only Food and Drug Administration-approved kit for HIV drug resistance testing by genotypic sequencing is commercially available through Visible Genetics, Inc. Genotyping sequencing alone is most likely an adequate test to assist in the therapeutic decision-making process for previous regimen failure, for treatment-naïve patients in areas of high prevalence of transmitted resistant virus, and for pregnant women. However, in exceptional cases of highly complex mutation patterns and extensive cross-resistance, it may be useful to obtain a phenotype test, because that result may more easily identify drugs to which virus is least resistant. There are no published clinical trials results on the usefulness of the so-called virtual phenotype over genotypic sequencing alone. Not only has the paradigm of viral pharmacogenomics in the form of HIV genotypic sequencing been useful in treating other viral diseases, but it is also important to the real-life implementation of the growing discipline of genomics or molecular medicine. The application of this paradigm to the thousands of potential therapeutic targets that have become available through the various human genome projects will certainly gradually change the landscape of diagnosis and management of many diseases, including cancer.

KW - Antiretroviral treatment

KW - Drug resistance testing

KW - HIV-1

KW - Mutations

KW - Protease

KW - Reverse transcriptase

KW - Viral fitness

KW - Virus infection

UR - http://www.scopus.com/inward/record.url?scp=0042338721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042338721&partnerID=8YFLogxK

U2 - 10.1615/JEnvPathToxOncol.v22.i3.40

DO - 10.1615/JEnvPathToxOncol.v22.i3.40

M3 - Article

C2 - 14529094

AN - SCOPUS:0042338721

VL - 22

SP - 201

EP - 234

JO - Journal of Environmental Pathology, Toxicology and Oncology

JF - Journal of Environmental Pathology, Toxicology and Oncology

SN - 0731-8898

IS - 3

ER -